The MarketWatch News Department was not involved in the creation of this content.-- Rezurock(R) (belumosudil tablets) now listed for public reimbursement, offering access to adult ...

Other CIBMTR presentations will include additional results from ACCESS study; a trial in progress update on the ACCELERATE trial (NCT06859424), a platform protocol for testing multiple PTCy-based ...

Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 ...

ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives ...

Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

Introduction: The occurrence of monoclonal gammopathies (MG) and oligoclonal (two or more monoclonal proteins) gammopathies (OG) might be triggered by some factors, such as immune recovery following ...

Incyte has expanded its support for projects tackling unmet needs to cover hidradenitis suppurativa (HS) patients, tightening ...

Pairing donors and recipients with mismatched blood types could hasten more life-saving stem cell transplants for patients ...

An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast Limited announced a scheduled meeting with the FDA to discuss ...

Doctors in Gurugram have achieved an 87% survival rate in curing children with Sickle Cell Disease using Bone Marrow ...

Sanofi is pleased to announce that Quebec has added Rezurock® (belumosudil tablets) to the list of medications covered by the ...